繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-830、SNP-840

SNP-830、SNP-840

Indication
Hepatotoxicity-free Analgesic
Product Advantages
1. Hepatotoxicity-free Acetaminophen prescription Combo
2. A new combination with great safety margin
Status
After the approval of SNP-810 Plan a clinical trial with / without bioequivalent study for NDA
Competitive Edge
1. No hepatotoxicity-free acetaminophen prescription Combo on the market
2. Acetaminophen prescription combos were requested by USFDA to reduce the dose to below 325 mg ( potency affected )
3. Remove or modify the FDA liver warning
4. Regain the AAP dose to 500 mg or more
5. Grab the market of other pain controllers
6. The two choose one license
Potential Market
Acetaminophen prescription Combo sales are 2.7 billion USD a year (US only)


体彩p5中奖新闻 双色球免费版 深圳风采2011014 12倍百家乐秘籍 甘肃11选5玩法规则 河北快三开奖结果经彩网 002079股票分析 北京快3玩法及中奖规则 最好玩的赛车游戏排名 江西时时彩三星综合走势图 青海体彩11任选5